To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo

Inclusion Criteria: * Informed consent obtained before any trial related activities * Healthy Chinese male subjects * Body mass index (BMI) between 19.0 and 27.0 kg/m2 (both inclusive) * Fasting plasma glucose less than 6.0 mmol/L * Non-smoker Exclusion Criteria: * Clinically significant abnormalities on pre-study clinical examination or any laboratory measurements during screening (any abnormality should be discussed with the clinical monitor) * Presence of diabetes, cancer or any clinically significant cardiac, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, dermatological, venereal, haematological, neurological, or psychiatric diseases or disorders * Blood pressure in supine position at the screening, after resting for 5 min, outside the ranges 90- 140 mmHg systolic and/or 40 - 90 mmHg diastolic * Pulse in supine position at the screening, after resting for 5 min, outside the range 40 - 100 times/min * Hepatitis B surface antigen, Hepatitis C antibodies or HIV antibodies positive.